Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 January 2019 | Story Leonie Bolleurs
Animal Conservation
A giraffe after a successful immobilisation capture being prepared for safe relocation.

From 2007 to 2014, the country experienced an exponential rise in rhino poaching – a growth of over 9,000%. Most illegal activities occur in the Kruger National Park.

 

Contributing to fight this battle is a group of five former students and colleagues from the UFS Department of Chemistry, now in the employment of Wildlife Pharmaceuticals. Situated in the Nelspruit area, Dr Inus Janse van Rensburg, Head of Research and Development; Lizette Janse van Rensburg, Head of Operations; Leo Kirsten, API expert; Dr Rikus Peens, API chemist; and Dr Chris Joubert, Laboratory Specialist, are working at this pharmaceutical manufacturing facility. The company specialises in the development, manufacturing, and end use of wildlife medicines.

 

With the medicines they develop, they are able to immobilise animals. Prof André Roodt, Discipline Head of the UFS Division of Inorganic Chemistry, who attended Indaba 9 with members of his research team in Skukuza, Kruger National Park, said wildlife species are being chemically immobilised for different reasons.

 

Prosecution of poachers

 

One example is of a rhino which was immobilised after a successful dehorning procedure by veterinarians and personnel of Wildlife Pharmaceuticals. As part of a programme to discourage poaching, selective DNA data collection is also conducted by some veterinarian groups for future use in the possible prosecution of individuals who are dealing with rhino horn. As soon as a rhino that was killed during poaching has been discovered, samples of the animal are obtained for a full analysis.

 

These samples are then stored on a database. Wherever rhino horn is confiscated (even internationally), the DNA is analysed, and the database may be consulted to see where the specific rhino was killed. The person in possession of the rhino horn may then be charged with the ‘killing’ of the original rhino.

 

Prof Roodt explained that the foundation of all medicines is based on active pharmaceutical ingredients (APIs) present in the finished pharmaceutical product, be it tablets, capsules, a syrup or a sterile injectable liquid. In accordance with local and international regulations and guidelines, chemists at API facilities are manufacturing these APIs globally.

 

Wildlife conservation

 

The APIs are respectively incorporated into registered finished pharmaceutical products, which are then used by registered veterinarians for chemical immobilisation and reversal of immobilisation in wildlife species.

 

According to Prof Roodt, the importance of developing appropriate chemical agents and the role of chemical manufacturing are crucial for animal conservation, with a scope far beyond the field of animal immobilisation, thus extending it to animal health, treatments, and vaccinations.

 

Besides saving our rhinos, wildlife species require immobilisation for different reasons. This can include, for example, wound treatment, relocation, and surgical procedures. “It is critical that the animals be immobilised to ensure limitation of stress to the animal, mitigate self-harm, allow safe handling of the animal, and for operator safety. These activities will be impossible to execute without chemical immobilisation of the animal,” said Prof Roodt.

 

Dr Janse van Rensburg, who received his PhD in the UFS Department of Chemistry in 2008, said the department, through exposing its students to, among others, complex equipment in labs as well as work in international labs to critically assess and benchmark their work against others, contributed to the success of his career at Wildlife Pharmaceuticals.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept